FREE SHIPPING ON ORDERS OVER $150

dihexa pnb-0408 c-met hgfr activator (also known as PNB-0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the blood–brain barrier and has shown synaptogenic effects in preclinical models. The often-quoted HGF-independent potentiation of EGFR action

$22.10

Quantity
- +
Description

This Dr

dihexa pnb-0408 c-met hgfr activator (also known as PNB-0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the bloodbrain barrier and has shown synaptogenic effects in preclinical models. The often-quoted HGF-independent potentiation of EGFR action

Studies suggest it activates lipolysis the process of breaking down stored fat and inhibits lipogenesis, which is the formation of new fat cells

dihexa pnb-0408 c-met hgfr activator (also known as PNB-0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the bloodbrain barrier and has shown synaptogenic effects in preclinical models. The often-quoted HGF-independent potentiation of EGFR action

New England Journal of Medicine, 373(23), 2247-2257

dihexa pnb-0408 c-met hgfr activator (also known as PNB-0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the bloodbrain barrier and has shown synaptogenic effects in preclinical models. The often-quoted HGF-independent potentiation of EGFR action

Users should review local laws and governing body policies before use

dihexa pnb-0408 c-met hgfr activator (also known as PNB-0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the bloodbrain barrier and has shown synaptogenic effects in preclinical models. The often-quoted HGF-independent potentiation of EGFR action

You may also like

recommand products